Thirty years in, the U.S., indeed the planet, is making great strides in HIV and AIDS research. Dr. Fauci's vision of an AIDS-free generation will only be realized with innovative biologic and biosimilar medicines that are effective in and accessible by all affected populations.
The U.S. pharmaceutical industry has worked hard to become an international leader in the production of biotech drugs. But as the nation introduces these medicines, we need to ensure that safety protocols are in place -- so that every patient has the opportunity to get healthy.
Today, too many families face President Reagan's "long goodbye" -- and too many Alzheimers' victims know, even as the disease begins to rob them of their memories, of the pain their families will face.
It is crucial that the health care communities in both the public and private sector transform their data collection and testing approaches to account for the overall changing face of the American population.
The United States will only realize this potential and remain the global leader in medical innovation if we maintain a strong environment for investment in the newest wave - biopharmaceuticals, also known as biologics.
The public option has received the lion's share of attention in the health care debate, but there's an equally important issue relating to generic drugs that could mean lifesaving drugs remain too expensive for all but the wealthy.
In Congress, I will work to support affordable prices on biologics, so that victims of cancer, HIV, diabetes, Parkinsons, rheumatoid arthritis, and multiple sclerosis can afford the medicine they need to stay alive.